Drug Profile
BI 1015550
Alternative Names: BI-1015550Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class 2 ring heterocyclic compounds; Alcohols; Amines; Anti-inflammatories; Antifibrotics; Chlorinated hydrocarbons; Cyclobutanes; Piperidines; Pyrimidines; Small molecules; Thiophenes
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Idiopathic pulmonary fibrosis; Interstitial lung diseases
Most Recent Events
- 13 Feb 2024 Boehringer Ingelheim completes a pharmacokinetics phase I trial (In volunteers) in Japan (PO) (NCT06139302)
- 12 Feb 2024 Boehringer Ingelheim plans a phase I pharmacokinetics trial for Idiopathic pulmonary fibrosis (PO) in June 2024 (NCT06241560)
- 02 Feb 2024 Boehringer Ingelheim plans the phase III FIBRONEER™-ON open-label extension trial for Idiopathic pulmonary fibrosis (PO), in July 2024 (NCT06238622)